M. C. Miller

发表

Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent

Robert W Veltri, Alan W Partin, Danil V Makarov, 2008, The Prostate.

Characterization of RNA‐binding motif 3 (RBM3) protein levels and nuclear architecture changes in aggressive and recurrent prostate cancer

Prakash Kulkarni, M. C. Miller, R. Veltri, 2020, Cancer reports.

Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma

Hartwig Huland, Markus Graefen, Robert W Veltri, 2003, Cancer.

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.

Robert W Veltri, M. Miller, R. Veltri, 2003, The Journal of urology.

Update on the appropriate staging evaluation for newly diagnosed prostate cancer.

J. Oesterling, M. Miller, R. Veltri, 1997, The Journal of urology.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis

Mikhail Gorbounov, Neil M Carleton, Robert W Veltri, 2018, The Prostate.

DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.

A. Partin, E. Humphreys, L. Mangold, 2009, Urology.

Understanding the Role of the Immune System in the Development of Cancer: New Opportunities for Population-Based Research

C. Marsit, K. Overvad, E. Weiderpass, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, J. Slaton, 1997, The Journal of urology.

Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage.

Robert W Veltri, Alan W Partin, A. Partin, 2002, Clinical chemistry.

Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.

R W Veltri, A W Partin, A. Partin, 1996, Urology.